v3.26.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Revenue      
Licensing and collaboration revenue $ 7,670,902 $ 103,204 $ 18,111,491
Operating expenses and income      
Research and development expenses (22,033,573) (28,781,412) (36,639,146)
Administrative expenses (7,075,624) (7,273,335) (8,672,843)
Other operating income, net     3,480,632
Loss from operations (21,438,295) (35,951,543) (23,719,866)
Interest and investment income 2,303,990 3,801,345 4,283,085
Interest expense (463,132) (851,874) (1,107,820)
Other income, net 323,988 466,620 1,843,437
Foreign exchange gain (loss), net 1,318,235 (906,212) 1,446,202
Change in fair value of warrant liabilities 47,941    
Loss before income tax (17,907,273) (33,441,664) (17,254,962)
Income tax benefit (expense) 297,860 17,553 (1,691,408)
Net loss attributable to Adagene Inc.'s shareholders (17,609,413) (33,424,111) (18,946,370)
Other comprehensive income (loss)      
Foreign currency translation adjustments, net of nil tax (1,387,928) 1,273,185 (950,783)
Total comprehensive loss attributable to Adagene Inc.'s shareholders (18,997,341) (32,150,926) (19,897,153)
Net Income (Loss) (17,609,413) (33,424,111) (18,946,370)
Net loss attributable to ordinary shareholders $ (17,609,413) $ (33,424,111) $ (18,946,370)
Weighted average number of ordinary shares used in per share calculation:      
Basic (in shares) 59,006,129 56,287,903 54,737,530
Diluted (in shares) 59,006,129 56,287,903 54,737,530
Net loss per ordinary share      
Basic (in dollars per share) $ (0.3) $ (0.59) $ (0.35)
Diluted (in dollars per share) $ (0.3) $ (0.59) $ (0.35)